Advertisement

Pathophysiologische Grundlagen und Prinzipien der Pharmakotherapie

  • M. Gerlach
  • P. Riederer

Zusammenfassung

Seit den ersten von Tretiakoff 1919 beschriebenen Befunden gilt die Schädigung der Substantia nigra (SN) als morphologisches Substrat der Parkinson-Krankheit (Synonyme: Morbus Parkinson, idiopathisches Parkinson-Syndrom) und anderer Parkinson-Syndrome, obwohl neuere Untersuchungen auch Schädigungen verschiedener anderer Kerngebiete aufgezeigt haben (Jellinger 1991, Gerlach et al. 1994, Braak et al. 1995). Die Ursachen des unaufhaltsam langsam fortschreitenden Unterganges dopaminerger, Neuromelanin-haltiger Neuronen der SN, der mit typischen Zytoskelettveränderungen in Form von Lewy-Körpern einhergeht, sind nur in Ansätzen bekannt. Lange Zeit gab es keine Möglichkeit, die charakteristischen motorischen Symptome Akinese, Rigor und Ruhetremor medikamentös zu beeinflussen, geschweige denn Ansätze, den progressiven Verlauf der Krankheit aufzuhalten, obwohl Kliniker des 19.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Agid Y, Javoy-Agid F, Ruberg M, Pillon B, Dubois B, Duyckaerts C, Hauw J-J, Baron J-C, Scatton B (1986) Progressive supranuclear palsy: anatomoclinical and biochemical considerations. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 191–206Google Scholar
  2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415–455PubMedCrossRefGoogle Scholar
  3. Birkmayer W, Riederer P (1975) Responsibility of extrastriatal areas for the appearance of psychotic symptoms. J Neural Transm 37: 175–181PubMedCrossRefGoogle Scholar
  4. Braak H, Braak E, Yilmazer D, Schultz C, De Vos RAI, Jansen ENH (1995) Nigral and extranigral pathology in Parkinson’s disease. J Neural Transm [Suppl] 46: 15–31Google Scholar
  5. Brücke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I (1993) SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT. Binding kinetics in the human brain. J Neural Transm [Gen Sect] 94: 137–146CrossRefGoogle Scholar
  6. Brun S, Gomries CG, Roos BE (1971) Studies of the monamine metabolism in the central nervous system in Jacob-Creutzfeld disease. Acta Neurol Scand 47: 642–645PubMedCrossRefGoogle Scholar
  7. Carisson A, Lundqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryp-tophan as reserpine antagonists. Nature 180: 1200CrossRefGoogle Scholar
  8. Degen HJ, Lesch KP, Riederer P (1996) Ratio of expression of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT) is shifted towards VMAT in the nigrostriatal system of Parkinson’s disease (PD) patients. J Neural Transm 103: XXVIIIGoogle Scholar
  9. Delong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neu-rosci 13: 281–285CrossRefGoogle Scholar
  10. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxy-tyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Wien Klin Wochenschr 38: 1236–1239Google Scholar
  11. Gassen M, Glinka Y, Pinchasi B, Youdim MBH (1996) Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 308: 219–225PubMedCrossRefGoogle Scholar
  12. Gerlach M, Riederer P (1993) The pathophysiological basis of Parkinson’s disease. In: Szelenyi I (ed) Inhibitors of monoamine oxidase B. Birkhäuser, Basel Boston Berlin, pp 25–50Google Scholar
  13. Gerlach M, Riederer P (1997) Parkinson-Krankheit — biochemische Konzepte. In: Fischer P-A (Hrsg) Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie. Editiones Roche, Basel Grenzach-Wyhlen, S 7–19Google Scholar
  14. Gerlach M, Riederer P, Youdim MBH (1992) The molecular pharmacology of L-deprenyl. Eur J Pharmacol [Mol Pharmacol] 226: 97–108CrossRefGoogle Scholar
  15. Gerlach M, Jellinger K, Riederer P (1994) The possible role of noradrenergic deficits in selected signs of Parkinson’s disease. In: Briley M, Marien M (eds) Noradrenergic mechanisms in Parkinson’s disease. CRC Press, Boca Raton Ann Arbor London Tokyo, pp 59–71Google Scholar
  16. Gerlach M, Riederer P, Youdim MBH (1995) Neuroprotective therapeutic strategies: comparison of experimental and clinical results. Bio-chem Pharmacol 50: 1–16CrossRefGoogle Scholar
  17. Gerlach M, Riederer P, Youdim MBH (1996) Molecular mechanisms for neurodegenera-tion: synergism between reactive oxygen species, calcium and excitotoxic amino acids. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Parkinson’s disease. Lippincott-Raven, Philadelphia New York, pp 177–194 (Adv Neurol 69)Google Scholar
  18. Jankovic J, Kirkpatrick JB, Blomquist KA, Langlais PJ, Bird ED (1985) Late-onset Haller-vorden-Spatz disease presenting a familial parkinsonism. Neurology 35: 227–234PubMedCrossRefGoogle Scholar
  19. Jellinger K (1988) Pathology of Parkinson’s syndrome. In: Calne DB (ed) Handbook of experimental pharmacology, vol 88. Springer, Berlin Heidelberg New York Tokyo, pp 47–112Google Scholar
  20. Jellinger KA (1991) Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14:153–197PubMedCrossRefGoogle Scholar
  21. Jellinger K, Paulus W (1991) Bedeutung der Ni-graveränderungen bei Parkinson-Syndromen. In: Fischer P (Hrsg) Parkinson-Krankheit und Nigraprozess. Editiones Roche, Basel Grenz-ach-Whylen, S 3–28Google Scholar
  22. Kish SJ, Chang W, Mirchandani L, Shannak K, Hornykiewicz O (1985) Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 18: 530–536PubMedCrossRefGoogle Scholar
  23. Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. N Engl J Med 318: 876–880PubMedCrossRefGoogle Scholar
  24. Lange KW, Rausch W-D, Gsell W, Naumann M, Oestreicher E, Riederer P (1994) Neuroprotection by dopamine agonists. J Neural Tansm 43: 183–201Google Scholar
  25. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E (1993) Neurotransmitters in basal ganglia and cortex of Alzheimer’s disease with and without Lewy bodies. Neurology 43: 1927–1934PubMedCrossRefGoogle Scholar
  26. Leenders KL (1995) PET-Untersuchungen bei der Parkinson-Krankheit. In: Fischer P-A (Hrsg) Parkinson-Krankheit. Bedeutung nichtdop-aminerger Funktionsstörungen. Editiones Roche, Basel Grenzach-Whylen, S 31–47Google Scholar
  27. Lloyd KG, Hornykiewicz O (1970) Parkinson’s disease: activity of L-Dopa decarboxylase in discrete brain regions. Science 170:1212–1213PubMedCrossRefGoogle Scholar
  28. Lloyd KG, Davidson L, Hornykiewicz O (1975) The neurochemistry of Parkinson’s disease: effect of L-Dopa therapy. J Pharmacol Exp Ther 195: 453–464PubMedGoogle Scholar
  29. Medori R, Rausch WD, Chan WW, Götz ME, Burger R, Heinemann T, Gerlach M, Riederer P (1995) Neuroprotective efficacy of pergolide in the MPTP mouse. J Neural Transm [Gen Sect] 102: XXXIGoogle Scholar
  30. Meldrum B, Garthwaite J (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci [A special report 1991]: 54–62Google Scholar
  31. Mizukawa K, Mcgeer EG, Mcgeer PL (1993) Autoradiographic study on dopamine uptake sites and their correlation with dopamine levels and their striata from patients with Parkinson’s disease, Alzheimer’s disease, and neurologically normal controls. Mol Chem Neuropathol 18: 133–144PubMedCrossRefGoogle Scholar
  32. Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A (1994) Bromocriptine protects mice against 6-hydroxy-dopamine and scavenges hydroxyl free radicals in vitro. Brain Res 657: 207–213PubMedCrossRefGoogle Scholar
  33. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J (1995) The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 38: 771–777PubMedCrossRefGoogle Scholar
  34. Olney JW (1978) Neurotoxicity of excitatory amino acids. In: Mcgeer EG, Olney JW (eds) Kainic acid as a tool in neurobiology. Raven Press, New York, pp 95–121Google Scholar
  35. Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann Neurol 39: 29–36CrossRefGoogle Scholar
  36. Rausch WD, Hirata Y, Nagatsu T, Riederer P, Jellinger K (1988) Human brain tyrosine hydroxylase: in vitro effects of iron and phosphorylating agents in the CNS of controls, Parkinson’s disease and schizophrenia. J Neu-rochem 50: 202–228Google Scholar
  37. Reynolds GP, Garrett NJ (1986) Striatal dopamine and homovanillic acid in Huntington’s disease. J Neural Transm 65: 151–155PubMedCrossRefGoogle Scholar
  38. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson’s disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38: 277–301PubMedCrossRefGoogle Scholar
  39. Riederer P, Rausch WD, Birkmayer W, Jellinger K, Seemann D (1978) CNS modulation of adrenal tyrosine hydroxylase in Parkinson’s disease and metabolic encephalopathies. J Neural Transm [Suppl] 14: 121–132Google Scholar
  40. Riederer P, Sofic E, Konradi C (1986) Neurobio-chemische Aspekte zur Progression der Parkinson-Krankheit: Post-mortem-Befunde und MPTP-Modell. In: Fischer PA (Hrsg) Spätsyn-drome der Parkinson-Krankheit. Editiones Roche, Basel, S 37–49Google Scholar
  41. Riederer P, Sofic E, Rausch WD, Hebenstreit G, Bruinvels J (1989) Pathobiochemistry of the extrapyramidal system: a „short note“ review. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy in Parkinson’s disease. Springer, Wien New York, pp 139–149 (Key Topics in Brain Research)CrossRefGoogle Scholar
  42. Sardar AM, Czudek C, Reynolds GP (1996) Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. NeuroReport 7: 910–912PubMedCrossRefGoogle Scholar
  43. Seeman P, Van Tol HH (1993) Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 6: 602–608PubMedGoogle Scholar
  44. Sharpe JA, Rewcastle NB, Lloyd KG, Hornykie-Wicz O, Hill M, Tasker RR (1973) Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation. J Neurol Sci 19: 275–286PubMedCrossRefGoogle Scholar
  45. Tanaka M, Sotomatsu A, Yoshida T, Hirai S (1995) Inhibitory effects of bromocriptine on phospholipid peroxidation induced by DOPA and iron. Neurosci Lett 183: 116–119PubMedCrossRefGoogle Scholar
  46. The Parkinson Study Group (1989) Effect of de-prenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364–1371CrossRefGoogle Scholar
  47. The Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328: 176–184CrossRefGoogle Scholar
  48. Tretiakoff MC (1919) Contribution à 1’étude de l’anatomie pathologique du locus niger de Soemmering. Thése, Université de ParisGoogle Scholar
  49. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Prasad M, Rajput A, Basran P (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson’s disease. Neurology 46: 1551–1556PubMedCrossRefGoogle Scholar
  50. Wilson JM, Levey AL, Rajput A, Ang L, Guttman M, Shannak K, Niznik HB, Hornykiewicz O, Pifl C, Kish SJ (1996) Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson’s disease. Neurology 47: 718–726PubMedCrossRefGoogle Scholar
  51. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M (1994) Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 62: 1034–1038PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • M. Gerlach
  • P. Riederer

There are no affiliations available

Personalised recommendations